Portage Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Portage Biotech
PRTG Stock  USD 4.41  0.15  3.29%   
Portage Biotech financial statements provide useful quarterly and yearly information to potential Portage Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Portage Biotech financial statements helps investors assess Portage Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Portage Biotech's valuation are summarized below:
Market Capitalization
7.3 M
Earnings Share
(68.17)
There are over one hundred nineteen available trending fundamental ratios for Portage Biotech, which can be analyzed over time and compared to other ratios. Active traders should verify all of Portage Biotech recent fundamental drivers against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. The Portage Biotech's current Market Cap is estimated to increase to about 367.1 M. The Portage Biotech's current Enterprise Value is estimated to increase to about 365.1 M

Portage Biotech Total Revenue

0.0

Check Portage Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Portage Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 59 K, Other Operating Expenses of 22 M or Total Operating Expenses of 22 M, as well as many indicators such as Price To Sales Ratio of 2 K, Dividend Yield of 0.0 or PTB Ratio of 61.11. Portage financial statements analysis is a perfect complement when working with Portage Biotech Valuation or Volatility modules.
  
Check out the analysis of Portage Biotech Correlation against competitors.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

Portage Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8.5 M8.9 M59 M
Slightly volatile
Total Current Liabilities3.5 M3.3 M1.6 M
Slightly volatile
Cash3.2 M5.8 M5 M
Slightly volatile
Non Current Assets Total91.8 K96.6 K48.7 M
Slightly volatile
Cash And Short Term Investments6.1 M5.8 M8.9 M
Pretty Stable
Common Stock Shares Outstanding24.6 M23.4 M8.6 M
Slightly volatile
Liabilities And Stockholders Equity8.5 M8.9 M59 M
Slightly volatile
Total Liabilities6.1 M5.1 M9.6 M
Slightly volatile
Total Current Assets7.1 M8.8 M10.2 M
Pretty Stable
Common Stock265 M252.4 M102.3 M
Slightly volatile
Short and Long Term Debt Total51.3 K54 K565.9 K
Very volatile
Non Currrent Assets Other41.9 K44.1 K162.6 K
Pretty Stable
Non Current Liabilities Total1.7 M1.8 M8.1 M
Slightly volatile
Other Current Assets3.2 M3 M1.3 M
Pretty Stable
Short Term Debt34.2 K36 K372.5 K
Slightly volatile
Accounts Payable304.4 K554.3 K308.1 K
Pretty Stable
Net Receivables42.6 K44.9 K281.9 K
Very volatile
Intangible Assets87.7 M93.9 M66.8 M
Slightly volatile
Other Liabilities20.8 M32.7 M14.1 M
Slightly volatile
Net Tangible Assets57.7 M89.6 M61 M
Slightly volatile
Long Term Debt4.1 M3.9 M1.8 M
Slightly volatile
Common Stock Total Equity106.8 M150.2 M75.2 M
Slightly volatile
Net Invested Capital3.4 M3.6 M37 M
Slightly volatile
Net Working Capital8.8 M5.5 M7.7 M
Very volatile
Deferred Long Term Liabilities93.9 M105.6 M115.2 M
Slightly volatile
Short and Long Term Debt128.2 K135 K445.6 K
Slightly volatile
Capital Stock176.2 M252.4 M145 M
Slightly volatile

Portage Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization59 K62.1 K13.2 M
Very volatile
Other Operating Expenses22 M21 M10.7 M
Slightly volatile
Total Operating Expenses22 M20.9 M10.7 M
Slightly volatile
Cost Of Revenue46.2 K48.6 K69.9 K
Slightly volatile
Interest Expense35 K36.8 K100.2 K
Very volatile
Selling General Administrative3.6 M6.5 M3.6 M
Slightly volatile
Selling And Marketing Expenses12.3 K12.9 K27.5 K
Slightly volatile
Research Development8.1 M14.4 M6.7 M
Slightly volatile
Minority Interest36.8 K38.7 K33.6 M
Slightly volatile

Portage Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow12.7 M12.1 M5.5 M
Slightly volatile
Depreciation98 K62.1 K159.4 K
Pretty Stable
End Period Cash Flow3.2 M5.8 M5 M
Slightly volatile
Stock Based Compensation3.4 M3 M2.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2 K3.3 K3.4 K
Slightly volatile
Days Sales Outstanding537455495
Slightly volatile
Average Payables248.1 K287.5 K347.5 K
Slightly volatile
Capex To Depreciation0.840.880.842
Slightly volatile
EV To Sales2 K3.3 K3.3 K
Slightly volatile
Payables Turnover0.110.10.0231
Slightly volatile
Sales General And Administrative To Revenue11.8514.2515.3585
Slightly volatile
Research And Ddevelopement To Revenue0.260.30.3228
Slightly volatile
Capex To Revenue0.00850.00890.3469
Slightly volatile
Cash Per Share0.270.282.6385
Pretty Stable
Days Payables Outstanding3.6 K3.7 K81.9 K
Slightly volatile
Intangibles To Total Assets0.620.740.7454
Slightly volatile
Current Ratio2.292.4143.542
Very volatile
Receivables Turnover1.011.060.8917
Slightly volatile
Graham Number4.434.6797.6038
Slightly volatile
Debt To Equity0.01280.01340.0202
Slightly volatile
Capex Per Share2.0E-42.0E-40.1375
Slightly volatile
Average Receivables90.9 K102.3 K126.6 K
Slightly volatile
Revenue Per Share0.130.140.3417
Slightly volatile
Interest Debt Per Share0.00420.00450.417
Slightly volatile
Debt To Assets0.00660.00690.0129
Slightly volatile
Operating Cycle537455495
Slightly volatile
Days Of Payables Outstanding3.6 K3.7 K81.9 K
Slightly volatile
Long Term Debt To Capitalization0.01790.03030.0182
Slightly volatile
Total Debt To Capitalization0.01260.01330.0189
Slightly volatile
Debt Equity Ratio0.01280.01340.0202
Slightly volatile
Quick Ratio2.292.4143.7185
Very volatile
Cash Ratio1.491.578.9338
Very volatile
Days Of Sales Outstanding537455495
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.770.91.0012
Pretty Stable
Fixed Asset Turnover9.1415.7515.8193
Pretty Stable
Debt Ratio0.00660.00690.0129
Slightly volatile
Price Sales Ratio2 K3.3 K3.4 K
Slightly volatile
Asset Turnover0.03130.0330.0281
Slightly volatile

Portage Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap367.1 M349.6 M360.8 M
Slightly volatile
Enterprise Value365.1 M347.8 M358.9 M
Slightly volatile

Portage Fundamental Market Drivers

Cash And Short Term Investments5 M

Portage Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
29th of July 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of July 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Portage Biotech Financial Statements

Portage Biotech stakeholders use historical fundamental indicators, such as Portage Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Portage Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Portage Biotech's assets and liabilities are reflected in the revenues and expenses on Portage Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Portage Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-433.8 K-412.1 K
Cost Of Revenue48.6 K46.2 K
Sales General And Administrative To Revenue 14.25  11.85 
Research And Ddevelopement To Revenue 0.30  0.26 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.14  0.13 
Ebit Per Revenue(13.21)(13.87)

Currently Active Assets on Macroaxis

EBRCentrais Electricas Brasileiras
HEHawaiian Electric Industries
VFCVF Corporation
BVHMFVistry Group PLC
SSentinelOne
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:
How To Invest In Portage
Details
Is Portage Stock a good investment?
Details
What is Portage Biotech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Portage Biotech Correlation against competitors.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(68.17)
Return On Assets
(0.19)
Return On Equity
(1.91)
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY